93
Participants
Start Date
October 7, 2020
Primary Completion Date
November 23, 2023
Study Completion Date
December 15, 2023
Cabozantinib 40 mg
All the subjects will be treated with the combination of cabozantinib and atezolizumab until disease progression, unacceptable toxicity or patient consent withdrawal (whichever occurs first).
MD Anderson Cancer Center, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Hospital Universitario Virgen de la Victoria, Málaga
Hospital General Universitario Morales Meseguer, Murcia
Hospital Universitario Central de Asturias, Oviedo
Hospital Universitario de Canarias, Santa Cruz de Tenerife
Hospital Universitario Marqués de Valdecilla, Santander
Hospital Universitario Virgen del Rocío, Seville
Hospital Universitario Miguel Servet, Zaragoza
Hospital Germans Trias i Pujol - ICO Badalona, Badalona
Hospital Duran i Reynals - ICO L'Hospitalet, L'Hospitalet de Llobregat
Hospital General Universitario Elche, Alicante
Hospital Universitari Vall d'Hebron, Barcelona
Collaborators (1)
Ipsen
INDUSTRY
Roche Pharma AG
INDUSTRY
Grupo Espanol de Tumores Neuroendocrinos
OTHER